LAVA Therapeutics (NASDAQ:LVTX) Rating Reiterated by HC Wainwright

LAVA Therapeutics (NASDAQ:LVTX)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Friday, Marketbeat reports. They currently have a $6.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 233.33% from the stock’s previous close.

LAVA Therapeutics Trading Down 4.3 %

Shares of LVTX stock opened at $1.80 on Friday. The company has a current ratio of 7.42, a quick ratio of 7.42 and a debt-to-equity ratio of 0.01. LAVA Therapeutics has a 1 year low of $1.13 and a 1 year high of $6.47. The stock has a fifty day moving average of $2.52 and a two-hundred day moving average of $2.33.

LAVA Therapeutics (NASDAQ:LVTX) last announced its quarterly earnings results on Tuesday, May 21st. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.23. LAVA Therapeutics had a negative return on equity of 51.90% and a negative net margin of 228.02%. The company had revenue of $6.99 million during the quarter. Equities analysts forecast that LAVA Therapeutics will post -1.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in LAVA Therapeutics stock. Pathway Financial Advisors LLC acquired a new position in LAVA Therapeutics (NASDAQ:LVTX) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 14,000 shares of the company’s stock, valued at approximately $47,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.